Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen - Summary - MDSpire

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen

  • By

  • Shai Shimony

  • Hari S. Raman

  • Yael Flamand

  • Julia Keating

  • Jonathan D. Paolino

  • Yannis K. Valtis

  • Andrew E. Place

  • Lewis B. Silverman

  • Stephen E. Sallan

  • Lynda M. Vrooman

  • Andrew M. Brunner

  • Donna S. Neuberg

  • Ilene Galinsky

  • Jacqueline S. Garcia

  • Eric S. Winer

  • Martha Wadleigh

  • Richard M. Stone

  • Jean M. Connors

  • Daniel J. DeAngelo

  • Marlise R. Luskin

  • October 31, 2024

  • 0 min

Share

Objective:

To describe the prevalence, risk factors, and clinical impact of venous thromboembolism (VTE) among adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated on pediatric-inspired regimens, with a specific focus on evaluating the role of heparin prophylaxis.

Key Findings:
  • 33.4% of patients experienced at least one VTE event, indicating a significant clinical concern.
  • Higher rates of elevated BMI were observed in patients with VTE (50.9% vs. 39.6%, p = 0.048), suggesting a potential risk factor.
  • Lower rates of hyperdiploid karyotype were found in patients with VTE (3.5% vs. 13.2%, p = 0.0038), which may influence treatment outcomes.
  • Patients treated on trial had a higher incidence of VTE (29.8% vs. 20.3%, p = 0.049), highlighting the need for tailored management strategies.
Interpretation:

The study highlights a significant incidence of VTE in AYAs with ALL treated with ASP, identifying specific risk factors and suggesting the need for targeted prophylactic strategies to improve patient outcomes.

Limitations:
  • Retrospective design may introduce bias.
  • Limited generalizability due to specific treatment protocols.
  • Potential confounding factors not fully controlled, including missing data.
Conclusion:

VTE is a common complication in AYAs with ALL on pediatric-inspired regimens, with specific risk factors identified. Further research is needed to optimize prophylaxis strategies, particularly in high-risk populations.

Original Source(s)

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen

  • by Shai Shimony, Hari S. Raman, Yael Flamand, Julia Keating, Jonathan D. Paolino, Yannis K. Valtis, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna S. Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M. Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin

  • October 31, 2024

Related Content

Evolution of 29 Anthropometric, Nutritional, and Cardiometabolic Parameters Among Morbidly Obese Adolescents 2 Years Post Sleeve Gastrectomy

Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?

Two genetic subtypes of childhood B-cell acute lymphoblastic leukemia (B-ALL) have long been associated with inferior treatment outcomes: Philadelphia chromosome-positive (Ph+) and ABL-class Philadelphia chromosome-like (Ph-like) B-ALL.

  • by

  • January 29, 2026

  • 3 min
Four-Year Outcomes of One-Anastomosis Gastric Bypass in Children and Adolescents with Obesity: Safety, Effectiveness, and Resolution of Obesity-Related Medical Conditions